Skip to main content
OpenTrials
Completed

NCT Number: NCT02066766

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam

This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Vietnam.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Novo Nordisk Investigational Site

Hanoi, Vietnam

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • People with type 2 diabetes mellitus (DM) who are being treated, with any of the non-pharmacological or pharmacological options, at a particular centre for at least 1 year and who have visited the centre within the last 3-6 months
  • Patients willing to sign informed consent form

Exclusion criteria

  • Previous participation in this study
  • Unable to comply with protocol requirements
  • Confirmed or suspected pregnancy

Treatment and study plan

No treatment given

Other

Patients will fill out a questionnaire by interview.

Primary outcomes

  1. Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7%

    Time frame: Evaluated at the first visit (only one study visit)

Secondary outcomes

  1. Mean Fasting Plasma Glucose (FPG) of patients

    Time frame: Evaluated at the first visit (only one study visit)

  2. Mean Postprandial Plasma Glucose (PPG) of patients

    Time frame: Evaluated at the first visit (only one study visit)

  3. Mean HbA1c of patients

    Time frame: Evaluated at the first visit (only one study visit)

  4. Proportion of patients having dyslipidemia

    Time frame: Evaluated at the first visit (only one study visit)

  5. Proportion of patients having hypertension

    Time frame: Evaluated at the first visit (only one study visit)

  6. Proportion of patients having cardiovascular complications

    Time frame: Evaluated at the first visit (only one study visit)

  7. Proportion of patients having peripheral vascular disease

    Time frame: Evaluated at the first visit (only one study visit)

  8. Proportion of patients having diabetic nephropathy

    Time frame: Evaluated at the first visit (only one study visit)

  9. Proportion of patients having diabetic eye complications

    Time frame: Evaluated at the first visit (only one study visit)

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Acronym: DiabCare Asia

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Feb 20, 2014
Registry last updated
Oct 23, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.